Montelukast, a Leukotriene-Receptor Antagonist, for the Treatment of Mild Asthma and Exercise-Induced Bronchoconstriction

1998555 citationsJournal Articlebronze Open Access

Authors

Jonathan A. Leff · Merck & Co., Inc., Rahway, NJ, USA (United States)

William W. Busse · University of Wisconsin–Madison

David S. Pearlman

Edwin A. Bronsky · American Medical Group Association

James P. Kemp · Allergy and Asthma Medical Group and Research Center

Leslie Hendeles · University of Florida

Robert J. Dockhorn · Research Medical Center

Abstract

As compared with placebo, once-daily treatment with montelukast provided significant protection against exercise-induced asthma over a 12-week period. Tolerance to the medication and rebound worsening of lung function after discontinuation of treatment were not seen.

Topics & Keywords

Asthma and respiratory diseases Respiratory and Cough-Related Research Allergic Rhinitis and Sensitization

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 339, Issue 3, pp. 147-152

DOI: 10.1056/nejm199807163390302

Field-Weighted Citation Impact: 28.42